MedTrace Logo

Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke

NCT00840671 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2010-12-28

No results posted yet for this study

Summary

It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.

Conditions

Interventions

DRUG

Cerebrolysin

Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.

DRUG

0.9% Saline Solution

0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.

Sponsors & Collaborators

  • JSW-Research Forschungslabor GmbH, Parkring 12, 8074 Grambach

    collaborator UNKNOWN

  • Ever Neuro Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Manfred Windisch, PhD · JSW Research Forschungslabor GmbH

  • Wilfried Lang, MD · Krankenhaus der Barmherzigen Brüder, 1020 Wien

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-03-31
Completion
2008-07-31

Countries

  • Austria
  • Croatia
  • Czechia
  • Slovakia
  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00840671 on ClinicalTrials.gov